Cayman Islands vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cayman Islands
0.2%
in 2024
United States Virgin Islands
0.2%
in 2024
Cayman Islands rank
98th
United States Virgin Islands rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cayman Islands
- United States Virgin Islands
How they compare
Cayman Islands currently reports 0.2% against 0.2% in United States Virgin Islands, a difference of 0.0%.
Across all 10 years both countries report, United States Virgin Islands has been ahead every year.
Cayman Islands ranks 98th and United States Virgin Islands ranks 98th of 246 countries.
Head to head by decade
| Decade | Cayman Islands | United States Virgin Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cayman Islands or United States Virgin Islands?
- Cayman Islands, at 0.2% against 0.2% in United States Virgin Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cayman Islands and United States Virgin Islands?
- 0.0%, with Cayman Islands ahead.
- How many years of comparable data are there for Cayman Islands and United States Virgin Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Cayman Islands and United States Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cayman Islands ranks 98th and United States Virgin Islands ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.